Cargando…

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

OBJECTIVE: To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial. METHODS: Adults with active AS and inadequate response/intolerance to two or more NSAIDs were rand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maksymowych, Walter P, Østergaard, Mikkel, Landewé, Robert, Barchuk, William, Liu, Ke, Tasset, Chantal, Gilles, Leen, Hendrikx, Thijs, Besuyen, Robin, Baraliakos, Xenofon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071516/ https://www.ncbi.nlm.nih.gov/pubmed/34352069 http://dx.doi.org/10.1093/rheumatology/keab543

Ejemplares similares

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial
por: Maksymowych, Walter P, et al.
Publicado: (2021)

Can erosions on MRI of the sacroiliac joints be reliably detected in patients with ankylosing spondylitis? - A cross-sectional study
por: Weber, Ulrich, et al.
Publicado: (2012)

Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients
por: Maksymowych, Walter P, et al.
Publicado: (2018)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Imaging of ankylosing spondylitis
por: Østergaard, Mikkel
Publicado: (2012)

New developments in ankylosing spondylitis—status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2021)

Filgotinib: A Clinical Pharmacology Review
por: Namour, Florence, et al.
Publicado: (2022)

Erratum to: New developments in Ankylosing spondylitis – Status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2022)

Update on the treatment of ankylosing spondylitis
por: Maksymowych, Walter P
Publicado: (2007)

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis
por: Braun, Jürgen, et al.
Publicado: (2017)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

What do we know about co-stimulatory and co-inhibitory immune checkpoint signals in ankylosing spondylitis?
por: Schütz, Christian, et al.
Publicado: (2023)

A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features
por: Han, Qing, et al.
Publicado: (2021)

The value of the sacroiliac joint area as a new morphological parameter of ankylosing spondylitis
por: Bang, Yun-Sic, et al.
Publicado: (2022)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
por: Combe, Bernard, et al.
Publicado: (2022)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial
por: Østergaard, Mikkel, et al.
Publicado: (2023)

What do biomarkers tell us about the pathogenesis of ankylosing spondylitis?
por: Maksymowych, Walter P
Publicado: (2009)

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
por: van der Heijde, Désirée, et al.
Publicado: (2009)

Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
por: Ramiro, Sofia, et al.
Publicado: (2013)

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
por: Namour, Florence, et al.
Publicado: (2018)

Progressive sacroiliitis due to accessory sacroiliac joint mimicking ankylosing spondylitis: A case report
por: Song, Ran, et al.
Publicado: (2019)

Comparison of sacroiliac CT findings in patients with and without ankylosing spondylitis aged over 50 years
por: Fakih, Olivier, et al.
Publicado: (2023)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
por: Baraliakos, Xenofon, et al.
Publicado: (2013)

Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
por: Baraliakos, X, et al.
Publicado: (2015)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
por: Marzo-Ortega, Helena, et al.
Publicado: (2020)

Tortuga
por: Girarte Martínez, Luis
Publicado: (2008)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
por: Hibi, Toshifumi, et al.
Publicado: (2023)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
por: Genovese, Mark, et al.
Publicado: (2018)

Gold threads around the sacroiliac joints: traces of attempts to relieve pain in a case of advanced ankylosing spondylitis
por: Yoo, Wan-Hee, et al.
Publicado: (2022)

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019)

Diagnostic Value of MRI of the Sacroiliac Joints in Juvenile Spondyloarthritis
por: Herregods, Nele, et al.
Publicado: (2016)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bn859sab3m8nknsm65fjrhqkrj